

## Discovery Report

Patent: EVE-PAT-2026-001 | Organiq Sweden AB

## 1 - DISCOVERY

QUERY	Auto-scan: Methylation
COMPOUND	TAMARIXETIN
DISCOVERY SCORE	276.280
ENGINE	DISCOVERY_v1.1
CORPUS VERSION	current
GENERATED	2026-05-20T02:00:02.610Z

## 2 - EVIDENCE

TARGETS	CYP1A2, AURKB, MUS, CYP1B1, RELA, NFKB1, CYP1A1, TLR4, NFKB2
PATHWAYS	Metabolism, Phase II - Conjugation of compounds, Methylation, Biological oxidations, Cytochrome P450 - arranged by substrate type, Phase I - Functionalization of compounds, Aromatic amines can be N-hydroxylated or N-dealkylated by CYP1A2, Xenobiotics
EVIDENCE SCORE	31.70
STUDIES	26

## X-VAULT EVIDENCE SEAL

SYSTEM	BiohacksAI   XVAULT_v1
DISCOVERY ID	DISC-tamarixetin-20260520-322604c5
EVENT HASH	deb8276d699891ff...1d9688a5
CHAIN HASH	af13d947803491df...0a61063d
PREV HASH	5ecb6e8ee7f5a275...6c597095
CORPUS VERSION	current
CORPUS ROOT	NOT_AVAILABLE...VAILABLE
VAULT INDEX	3106
SEALED AT (UTC)	2026-05-20T02:00:02.647Z

## - VERIFICATION

This document is cryptographically sealed by the BiohacksAI X-Vault Evidence Engine. The discovery payload hash and corpus Merkle root can be independently verified.

Verify at: [eveverified.com/verify](https://eveverified.com/verify)

Verification fingerprint: deb8276d699891ff...1d9688a5

